alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-END>                               MAR-31-1999
<CASH>                                       3,402,151
<SECURITIES>                                         0
<RECEIVABLES>                                  389,815
<ALLOWANCES>                                         0
<INVENTORY>                                  9,255,507
<CURRENT-ASSETS>                             3,431,810
<PP&E>                                      12,690,656
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                              29,722,798
<CURRENT-LIABILITIES>                        6,719,768
<BONDS>                                      5,966,891
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       497,529
<OTHER-SE>                                  16,538,610
<TOTAL-LIABILITY-AND-EQUITY>                29,722,798
<SALES>                                     12,545,759
<TOTAL-REVENUES>                            12,545,759
<CGS>                                        8,000,447
<TOTAL-COSTS>                               13,150,341
<OTHER-EXPENSES>                                69,512
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                              (674,094)
<INCOME-TAX>                                   229,111
<INCOME-CONTINUING>                          (444,983)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (444,983)
<EPS-PRIMARY>                                   (0.09)
<EPS-DILUTED>                                   (0.09)
        

</TABLE>
Exhibit
31.3


CERTIFICATIONS





I, W.
Thomas Amick, certify that:





1.      I
have reviewed this Amendment No. 1 on Form 10-K/A for the fiscal year ended
December 31, 2009 of Discovery Laboratories, Inc.; and





2.      Based on
my knowledge, this report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading
with respect to the period covered by this report.





Date:  April
      30, 2009
              /s/ W. Thomas AmickW.
      Thomas AmickChairman
      of the Boardand
      Chief Executive Officer
AOT A35L007-14 - Appendix A

Airline:

Program:

MSN:

Activation ok? 

(colour indicator)

PN MFG Date Lot Number Yes or No

ATA35 - chemical oxygen generators activation results

How many generators activated correctly:

How many generators failed:

Generators info
PUBLIC LAW 116–2—JAN. 18, 2019 133 STAT. 5 

LEGISLATIVE HISTORY—H.R. 251: 

CONGRESSIONAL RECORD, Vol. 165 (2019): 

Jan. 8, considered and passed House. 

Jan. 16, considered and passed Senate, amended. 

Jan. 17, House concurred in Senate amendments. 

Æ 

Public Law 116–2 

116th Congress 

An Act 

To extend by 15 months the Chemical Facility Anti-Terrorism Standards Program 

of the Department of Homeland Security, and for other purposes. 

Be it enacted by the Senate and House of Representatives of 

the United States of America in Congress assembled, 

SECTION 1. SHORT TITLE. 

This Act may be cited as the ‘‘Chemical Facility Anti-Terrorism 

Standards Program Extension Act’’. 

SEC. 2. EXTENSION OF CHEMICAL FACILITY ANTI-TERRORISM STANDARDS PROGRAM OF THE DEPARTMENT OF HOMELAND SECURITY. 

Section 5 of the Protecting and Securing Chemical Facilities 

from Terrorist Attacks Act of 2014 (Public Law 113–254; 6 U.S.C. 

621 note) is amended by striking ‘‘4 years’’ and inserting ‘‘5 years 

and 3 months’’. 

Approved January 18, 2019. 

6 USC 101 note. 

Chemical Facility 

Anti-Terrorism 

Standards 

Program 

Extension Act. 

Jan. 18, 2019 

[H.R. 251] 


ralbany on LAP520R082 with PUB LAWS PDF
#### § 331.1 Scope.

An over-the-counter antacid product in a form suitable for oral administration is generally recognized as safe and effective and is not misbranded if it meets each of the following conditions and each of the general conditions established in § 330.1 of this chapter.
# L_2019163DE.01011201.xml

| 20.6.2019 | DE | Amtsblatt der Europäischen Union | L 163/112 |
| --- | --- | --- | --- |

20.6.2019

DE

Amtsblatt der Europäischen Union

L 163/112

---

Berichtigung der Verordnung (EU) 2019/6 des Europäischen Parlaments und des Rates vom 11. Dezember 2019 über Tierarzneimittel und zur Aufhebung der Richtlinie 2001/82/EG

(
  Amtsblatt der Europäischen Union L 4 vom 7. Januar 2019
  )

Seite 103, Artikel 105 Absatz 3

Anstatt:

„(3)   Eine tierärztliche Verschreibung wird erst nach einer klinischen Prüfung oder ...“

muss es heißen:

„(3)   Eine tierärztliche Verschreibung wird erst nach einer klinischen Untersuchung oder ...“.

Seite 123, Artikel 152 Absatz 2

Anstatt:

„(2)   Gemäß der Richtlinie 2001/82/EG oder der Verordnung (EG) Nr. 726/2004 in Verkehr gebrachte Tierarzneimittel dürfen — auch wenn sie der vorliegenden Verordnung nicht entsprechen — ab dem 29. Januar 2027 noch fünf Jahre lang bereitgestellt werden.“

muss es heißen:

„(2)   Gemäß der Richtlinie 2001/82/EG oder der Verordnung (EG) Nr. 726/2004 in Verkehr gebrachte Tierarzneimittel dürfen — auch wenn sie der vorliegenden Verordnung nicht entsprechen — bis zum 29. Januar 2027 bereitgestellt werden.“

---
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1660 Propyl gallate. ( a ) Propyl gallate is the *n*-propylester of 3,4,5-trihydroxybenzoic acid (C10H12O5). Natural occurrence of propyl gallate has not been reported. It is commercially prepared by esterification of gallic acid with propyl alcohol followed by distillation to remove excess alcohol.
( b ) The ingredient meets the specifications of the “Food Chemicals Codex,” 3d Ed. (1981), pp. 257-258, which is incorporated by reference. Copies may be obtained from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or may be examined at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) The ingredient is used as an antioxidant as defined in § 170.3(o)(3) of this chapter.
( d ) The ingredient is used in food at levels not to exceed good manufacturing practice in accordance with § 184.1(b)(1). Good manufacturing practice results in a maximum total content of antioxidants of 0.02 percent of the fat or oil content, including the essential (volatile) oil content, of the food.
( e ) Prior sanctions for this ingredient different from the uses established in this section, or different from that stated in part 181 of this chapter, do not exist or have been waived.
[42 FR 14653, Mar. 15, 1977, as amended at 44 FR 52826, Sept. 11, 1979; 49 FR 5613, Feb. 14, 1984]
§ 320.36 Requirements for maintenance of records of bioequivalence testing. ( a ) All records of in vivo or in vitro tests conducted on any marketed batch of a drug product to assure that the product meets a bioequivalence requirement shall be maintained by the manufacturer for at least 2 years after the expiration date of the batch and submitted to the Food and Drug Administration on request.
( b ) Any person who contracts with another party to conduct a bioequivalence study from which the data are intended to be submitted to FDA as part of an application submitted under part 314 of this chapter shall obtain from the person conducting the study sufficient accurate financial information to allow the submission of complete and accurate financial certifications or disclosure statements required under part 54 of this chapter and shall maintain that information and all records relating to the compensation given for that study and all other financial interest information required under part 54 of this chapter for 2 years after the date of approval of the application. The person maintaining these records shall, upon request for any properly authorized officer or employee of the Food and Drug Administration, at reasonable time, permit such officer or employee to have access to and copy and verify these records.
[42 FR 1635, Jan. 7, 1977. Redesignated at 57 FR 18001, Apr. 28, 1992, as amended at 63 FR 5252, Feb. 2, 1998]
<PAGE>   1
                                                                    EXHIBIT 23.2


                  CONSENT OF INDEPENDENT CHARTERED ACCOUNTANTS



The Board of Directors
Intrawest Corporation

        We consent to the incorporation by reference in the Registration
Statement on Form S-8 of Intrawest Corporation pertaining to the Intrawest
401(k) Retirement Plan of our report dated September 10, 1998, which report
appears in the June 30, 1998 annual report on Form 40-F of Intrawest
Corporation.

/s/ KPMG LLP

Chartered Accountants

Vancouver, Canada
September 22, 1999
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM GULFWEST OIL
COMPANY'S  QUARTERLY  REPORT FILED ON FORM 10-Q FOR THE QUARTER ENDED  SEPTEMBER
30,1997  AND IS  QUALIFIED  IN ITS  ENTIRETY  BY  REFERENCE  TO  SUCH  FINANCIAL
STATEMENTS.
</LEGEND>
<CIK>                         0000813779
<NAME>                        0
<MULTIPLIER>                  1              
<CURRENCY>                    0              
       
<S>                          <C>
<PERIOD-TYPE>                 9-MOS 
<FISCAL-YEAR-END>             DEC-31-1996                
<PERIOD-START>                JUL-1-1997                 
<PERIOD-END>                  SEP-30-1997              
<EXCHANGE-RATE>               1                 
<CASH>                        100,764                 
<SECURITIES>                  0                 
<RECEIVABLES>                 688,669                 
<ALLOWANCES>                  0                 
<INVENTORY>                   0                 
<CURRENT-ASSETS>              970,312                 
<PP&E>                        17,846,630                 
<DEPRECIATION>                2,136,293                 
<TOTAL-ASSETS>                16,706,815                 
<CURRENT-LIABILITIES>         5,334,774                 
<BONDS>                       0                 
<PREFERRED-MANDATORY>         0                 
<PREFERRED>                   54                 
<COMMON>                      1,753                 
<OTHER-SE>                    3,194,758                 
<TOTAL-LIABILITY-AND-EQUITY>  16,706,815                 
<SALES>                       3,132,514                 
<TOTAL-REVENUES>              4,229,640                 
<CGS>                         0                 
<TOTAL-COSTS>                 4,157,467                 
<OTHER-EXPENSES>              0                
<LOSS-PROVISION>              0                
<INTEREST-EXPENSE>            (781,558)                 
<INCOME-PRETAX>               (682,295)                
<INCOME-TAX>                  0               
<INCOME-CONTINUING>           (682,295)                 
<DISCONTINUED>                0                 
<EXTRAORDINARY>               0                 
<CHANGES>                     0                 
<NET-INCOME>                  (682,295)                 
<EPS-PRIMARY>                 (.48)                 
<EPS-DILUTED>                 (.48)                
        

</TABLE>
EXHIBIT 99.1


                     Investment Properties Associates Closes
                      Sale of 1328 Broadway, New York, NY -
                 Announces Record Date for Special Distribution


New York, New York, January 18, 2000...Investment Properties Associates (IPA)
announced today that it has concluded the sale of its undivided fifty percent
interest as a tenant in common in 1328 Broadway, New York, NY for $43,500,000.
The purchaser is 1328 Broadway Associates, LLC.

An IPA spokesman said that the sales proceeds would be used to first pay
mortgage debt, closing costs and other commitments, aggregating approximately
$7,000,000. IPA will make a special distribution to holders of record of its
participations of partnership interests as of the close of business on January
31, 2000. It is anticipated that such distribution will be approximately $22.00
per participation interest and will be paid on February 17, 2000.

IPA understands that Nasdaq Stock Market rules require that, in the case of this
special distribution, the PPIs will trade ex-dividend one business day after the
payment date, which is February 17, 2000. Holders of PPIs who sell them before
the ex-dividend date (February 18, 2000) will transfer the right to receive the
special distribution to the buyers of PPIs in connection with the sale of the
PPIs. It should also be noted that on the ex-dividend date for this special
distribution, the price of the PPIs is expected to reflect the special
distribution and to trade below the current price.

The sale of 1328 Broadway was approved by all of the general partners of IPA
including ScogBell AG, Inc., Irving Schneider and Minlyn, Inc. Helmsley-Spear,
Inc. represented IPA in this transaction.

IPA was created in 1969 by Harry Helmsley and Irving Schneider. In addition to
1328 Broadway, IPA owns approximately 900,000 square feet of commercial office
buildings in New York and New Jersey. Irving Schneider said that IPA was
continuing to explore the possible sale of one or more or all of its properties,
but there could be no assurances that any such sale will be concluded.

Contact:     Irving Schneider - (212) 880-0151
             General Partner, Investment Properties Associates
             Co-Chairman & Chief Operating Officer, Helmsley-Spear, Inc., Agent

             Robert Hecht - (212) 880-0276
             Chief Financial Officer, Investment Properties Associates
             Vice President of Finance, Helmsley-Spear, Inc., Agent
#### § 558.295 Iodinated casein.

(a) *Specifications.* Type A medicated article containing iodinated casein.

(b) *Sponsor. See* No. 017762 in § 510.600(c) of this chapter.

(c) *Conditions of use* —

(1) *Ducks* —

| Amount in grams/ton | Indications for use | Limitations | Sponsor |
| --- | --- | --- | --- |
| (i) 100 to 200 | Growing ducks: For increased rate of weight gain | | 017762 |
| (ii) [Reserved] | | | |

(2) *Dairy cows* —

| Amount in grams/pound | Indications for use | Limitations | Sponsor |
| --- | --- | --- | --- |
| (1) 0.5 to 1.5 per 100 lb of body weight | Dairy cows: For increased milk production | This drug is effective for limited periods of time, and the effectiveness is limited to the declining phase of lactation. Administration must be accompanied with increased feed intake. Administration may increase heat sensitivity of the animal | 017762 |
| (2) [Reserved] | | | |

[85 FR 45309, July 28, 2020, as amended at 86 FR 14823, Mar. 19, 2021]
# Front side BMS board S S **C1 IC6**  **IC5**

**IC4 IC9**  **IC2 IC3 IC14** 

**IC16 IC17**  IC19 **CN -**  **1 CN**  **- 2** 

**C2 C3** 
**IC1 IC7**  **IC4**

**IC7 IC8** 

**IC10 IC10**  **IC11 T1**  **IC12 IC13** 

**IC15 IC16**  IC19

**IC18**IC 2,3,4 -AQW210 623 IC1 - MC9S12DG128MPV - ND C1 - PCE3155TR- ND

C2 - PCE3155TR- ND C3 - PCE3155TR- ND IC5 - IC6 - 495 - 1868 -2 - ND IC7 - TLE42754D - ND C3 - PCE3155TR- ND

IC8 - 497 - 1548 - 1 - ND IC10 - 160 - 1305 - 5 - ND IC9 - IPS041L- ND

IC1 1 - 516 - 1731 - 1 - NDIC13 - 631 - 101 1 - 6 - ND IC12 - 601636 T1 - 81 1 - 1556 - 5 - ND IC18, IC19 - MM74HC14SJX- ND CN1, CN2 - WM3809 - ND

IC14 - 606 SS 21 IC13 - 631 - 101 1 - 6 - ND

IC15 - 497 - 11 70 -2 - ND IC16, IC17 - OP

A343UA/2K5 - ND

# 21 mixed value capacitors

**7 2**  **2**

**3 2**  **1 1**  **3 2** **12**
**1** 

# 26 mixed resistors

**10 1**  **1 1** 

# Other side of the board

**IC20 IC21 IC22 IC23**  **IC24 IC25 IC26**  **IC27 IC32**  **IC28 IC29 IC30**  **IC31 IC33**  **IC34**IC20, IC21, IC22, IC23 - 296 - 17563 -2 - ND IC28, IC29, IC30 - 255 -2130 -2 - ND IC32, IC33, IC34 - MM74HC14SJX- ND IC31 - IPS041L - ND

# 47 mixed capacitors

**5 3**  **9**

**27 7** 

# 43 mixed value resistors

**4 1** 
**19**

**15 4**
[No. 15829-2-III.

Division Three.

December 30, 1997.]

#### The State of Washington, *Respondent,*v. Michael Luther Woosley, *Appellant.*

Appeal from a judgment of the Superior Court for Grant County, No. 95-1-00445-8, Evan E. Sperline, J., entered April 1, 1996. *Affirmed*by unpublished opinion per Sweeney, C.J., concurred in by Schultheis and Brown, JJ.
EXHIBIT 99.1
                                  CERTIFICATION
<PAGE>
                                  EXHIBIT 99.1
                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
                    AS ADOPTED PURSUANT TO SECTION 906 OF THE
                         SARBANES-OXLEY ACT OF 2002

In  connection   with the quarterly  report of Avitar,  Inc. (the  "Company") on
Form10-QSB for the period ending  December 31, 2002 as filed with the Securities
and  Exchange   Commission  on the date hereof  (the   "Report"),   I, Peter P.
Phildius,  Chief  Executive Officer  of the Company, and I, Jay C.  Leatherman,
Jr.,  Chief  Financial   Officer  of  the  Company   certify,   pursuant  to  18
U.S.C. Section  1350, as adopted pursuant to Section 906 of the   Sarbanes-Oxley
Act of 2002, to my knowledge, that:

     (1) The Report fully   complies  with the   requirements   of Section 13(a)
or15(d) of the Securities Exchange Act of 1934; and

     (2)  The  information  contained  in the  Report  fairly  presents,  in all
material  respects,  the  financial  condition and results of operations of the
Company.

Date: February 13, 2003

 /s/ Peter P. Phildius
 ---------------------
 Peter P. Phildius Chief
 Executive Officer

 /s/ Jay C. Leatherman, Jr.
 -------------------------
 Jay C. Leatherman, Jr.
 Chief Financial Officer (Principal Financial
 and Accounting Officer), Secretary
EXHIBIT 32.1



                            CERTIFICATION PURSUANT TO
                            18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



     In  connection  with the  Quarterly  Report  of  Tonga  Capital  Corp  (the
"Company")  on Form  10-QSB/A for the period  ending June 30, 2006 as filed with
the Securities  and Exchange  Commission on the date hereof (the  "Report").  I,
Barent W. Cater, President and Chief Executive Officer of the company,  certify,
pursuant  to 18 USC  Section  1350,  as adopted  pursuant  to Section 906 of the
Sarbanes-Oxley Act of 2002, that to the best of my knowledge and belief.

        (1)     The Report fully complies with the requirements of Section 13(a)
                or 15(d) of the Securities Exchange Act of 1934; and

        (2)     The information  contained in the Report fairly presents, in all
                material  respects,  the  financial  condition  and  results  of
                operations of the Company.




                                         /s/ Barent W. Cater
                                         --------------------------------
                                         Barent W. Cater, President and
                                         Chief Executive Officer
Dated: April 10, 2007
* Pursuant to 5 TH C IR . R. 47.5, the court has determined that

this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR . R. 47.5.4. United States Court of Appeals

Fifth Circuit 

## FILED August 10, 2004 Charles R. Fulbruge III Clerk IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 03-11330 Summary Calendar

ALANDA JABAR CLAYTON, Petitioner-Appellant,

versus L. E. FLEMING, Warden, Federal Medical Center-Fort Worth, Respondent-Appellee.

-------------------- Appeal from the United States District Court for the Northern District of Texas USDC No. 4:03-CV-1241-A

-------------------- Before EMILIO M. GARZA, BENAVIDES and CLEMENT, Circuit Judges.

PER CURIAM: * Alanda Jabar Clayton, federal prisoner # 13570-064, appeals the district court’s denial of his 28 U.S.C. § 2241 petition alleging that his constitutional rights were violated when the Bureau of Prisons (“BOP”) denied him a one-year sentence reduction, pursuant to 18 U.S.C. § 3621(e), after initially informing him that he was eligible for such a reduction. Clayton argues that the Supreme Court decision in Lopez v. Davis , 531 U.S. 230 (2001), was impermissibly appliedNo. 03-11330 -2- retroactively to deprive him of eligibility for a one-year reduction in his sentence. Contrary to Clayton’s belief, Lopez did not create a new law that denied him eligibility for early release under 18 U.S.C. § 3621(e). Because Lopez merely declared permissible a regulation that had gone into effect prior to Clayton’s conviction, there is no retroactivity issue here. Clayton argues that when his sentence was recalculated he acquired a liberty interest in early release and that the subsequent change in his eligibility status for early release violated his due process rights. His claims fail because there is no protected liberty interest in early release under 18 U.S.C. § 3621(e). See Rublee v. Fleming , 160 F.3d 213, 216 (5th Cir. 1998); Venegas v. Henman , 126 F.3d 760, 765 (5th Cir. 1997). Accordingly, the district court did not err in denying Clayton’s petition, and its judgment is AFFIRMED.
### Hydrogeologic reconnaissance of Poro Point and vicinity, Luzon Island, Philippines

By: George Frank Worts

                            https://doi.org/10.3133/wsp1608E

#### Links

-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Plate:  **Plate 1**                            (pdf)
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.